Jul. 9 at 2:30 PM
$APVO I know some may read this and just call me a hopeless pumper, but I couldn't care less. I don't think this will do anything of note for a few months...could even fade below
$2, but as soon as their primary therapeutic is advanced in trials to the next phase, I believe we could see a number well beyond
$420...with the current float, could even be 4 figures. A drug that send cancer into remission is worth billions...billions!....keep that in mind. This has nothing to do with company fundamentals...it's all about that intrinsic valuation.